Jade Biosciences, Inc. (JBIO) stock
Close on Nov 11, 2026Market cap $1.05BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.05B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.39
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$153.24M
- EPS, diluted
- -$3.19
- Free cash flow
- -$94.89M
- Book value per share
- $7.21
- Diluted shares
- 61M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $16.40
- Open
- $16.40
- Day's range
- $15.99 – $17.16
- Volume
- 678,968
- Average volume (20 days)
- 837,660
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 0.80
- 52-week range
- $8.95 – $28.00
- RSI (14 days)
- 62.7
- Volatility (1 year)
- 72.0%
- Relative volume
- 0.75×
- WACC
- 8.9%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | JBIO | S&P 500 | Difference | JBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.9% | -2.4% | +17.4 pts | ||
| 3 months | -26.0% | -1.2% | −24.8 pts | ||
| Year to date | +7.2% | +12.3% | −5.1 pts | ||
| 1 year | +68.8% | +12.4% | +56.3 pts | ||
| 3 years | -95.7% | +78.8% | −174.5 pts | -65.1% | +21.4% |
| 5 years | -97.3% | +75.2% | −172.4 pts | -51.3% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Jade Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Update
- Results
About Jade Biosciences
Pharmaceutical Preparations
Jade Biosciences is a clinical-stage biopharmaceutical company that discovers and develops biologic therapies to treat autoimmune disorders. The company focuses on monoclonal antibody candidates engineered to improve potency and pharmacokinetic properties over existing alternatives. Its lead product candidate, JADE101, targets a cytokine called APRIL to treat IgA nephropathy, a progressive kidney disease. Its second product candidate, JADE201, targets the BAFF receptor through cellular cytotoxicity and signaling pathway inhibition to address conditions such as rheumatoid arthritis. A third development program, JADE301, targets an undisclosed biological pathway. The company directs its investigational therapies toward patients suffering from serious autoimmune conditions.
Company profile, executives and historyJade Biosciences stock: common questions
What is Jade Biosciences's stock price?
JBIO closed at $16.54 on Nov 11, 2026, up 0.85% on the day. Over the past 52 weeks it traded between $8.95 and $28.00.
What is Jade Biosciences's market cap?
Jade Biosciences was worth $1.05B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is JBIO's P/E ratio?
Jade Biosciences lost money over fiscal 2025 (diluted EPS -$3.19), so it has no meaningful P/E ratio.
Does Jade Biosciences pay a dividend?
No. Jade Biosciences has not paid a cash dividend over the last twelve months.
When does Jade Biosciences report earnings next?
Jade Biosciences is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has JBIO stock performed over the past year?
Including dividends, JBIO returned +68.8% over the past year, against +12.4% for the S&P 500.
How many JBIO shares are sold short?
10M shares were sold short at the latest FINRA report, 21.28% of the float, or 14.1 days of average trading volume.
Who are Jade Biosciences's competitors?
Companies most similar to Jade Biosciences by business, industry and size include CLYM, VERA, VRDN, DMRA, QTTB.
See a number that looks wrong?